生物类似阿达利穆马布的可用性与预算节省有关吗? 对14个国家的差异分析
Hyunjung Woo1, Gyeongseon Shin1, Donghwan Lee2
1College of Pharmacy, Ewha Womans University, Seoul, South Korea.
概括
引入生物类似的阿达利穆马布导致14个国家大幅节省预算,减少了14%的支出,但没有减少患者获得该药物的机会.
科学领域:
- 药物经济学 药物经济学
- 卫生经济学 卫生经济学
- 制药政策 制药政策
背景情况:
- 阿达利穆马布是广泛用于各种炎症状况的生物药物.
- 生物类似阿达利穆马布的出现为医疗保健系统节省成本提供了机会.
- 了解采用生物类似药物的经济影响对于配方决策和预算规划至关重要.
研究的目的:
- 评估生物类似药物阿达利木马布可用性对阿达利木马布总体支出的影响.
- 量化预算节约和与生物类似物阿达利木马布相关的消费模式变化.
- 分析支出变化的驱动因素,包括价格,数量和药物组合.
主要方法:
- 分析跨国综合数据分析系统 (MIDAS) -IQVIA从2018年第四季度到2019年第四季度的数据.
- 在14个高收入和中高收入国家的阿达利穆马布支出和消费的比较.
- 使用差异差异设计,比较具有和没有生物类似物阿达利穆马布可用性的国家.
主要成果:
- 使用生物类似的阿达利穆马布的国家经历了支出显著下降 (人均国内生产总值为-371.0美元) 和消费显著增加 (每千人口1.0个单位).
- 在生物类似药可供的国家,阿达利穆马布的支出下降了14%,主要是由于价格下降 (-15%) 和药物组合效应 (-12%).
- 相比之下,没有生物类似物阿达利穆马布的国家的支出增加了4%,主要是由于消费量增加 (+6%).
结论:
- 生物类似的阿达利穆马布的可用性与医疗保健支出减少密切相关.
- 生物类似药的采用并没有对阿达利穆马布的消费产生负面影响,这表明患者继续获得治疗.
- 这些发现支持生物类似药阿达利穆马布在高收入和中高收入国家带来的经济效益.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130
Bioavailability: Overview
2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
Pharmacovigilance
843
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
843
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
66
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
66


